FIND-CKD investigators reported a 23% relative risk reduction in a kidney-cardiovascular composite outcome with finerenone use in patients with CKD but no diabetes -- a key secondary clinical endpoint ...
Patients with chronic kidney disease (CKD) stages 3b or 4 experienced slower decline in estimated glomerular filtration rate 20 months after enrollment in a value-based kidney care program. Objectives ...
Three major studies showed that finerenone could provide kidney and CV benefits for a wider range of patients with chronic ...
The usual glomerular filtration rate (GFR) threshold could be applied for predicting patient outcomes based on measured (mGFR) values, a retrospective observational cohort study indicated. Among 6,174 ...
Bayer announced today full results from the Phase III FIND-CKD trial investigating KERENDIA ® (finerenone) in adults with non-diabetic chronic kidney disease (nd-CKD) who were also receiving ...
In randomized trials, finerenone, a nonsteroidal mineralocorticoid receptor antagonist, improved kidney and cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease (CKD).
Verywell Health on MSN
5 stages of chronic kidney disease (CKD) from first symptoms to kidney failure
Stage 1 CKD often doesn't cause noticeable symptoms but requires measures to preserve kidney function. Managing high blood ...
A 16-µg dose of lubiprostone, a medication used in the management of constipation, improved or preserved estimated glomerular filtration rate (eGFR) in patients with chronic kidney disease (CKD), ...
Please provide your email address to receive an email when new articles are posted on . Adults in the semaglutide group with low eGFR and higher UACR had significant risk reductions for the composite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results